| CDM02 vs Kazuya | 32–25 | 56.14% |
| CDM02 vs Jin | 25–27 | 48.08% |
| CDM02 vs Heihachi | 23–13 | 63.89% |
| CDM02 vs Reina | 20–15 | 57.14% |
| CDM02 vs Law | 16–12 | 57.14% |
| CDM02 vs Steve | 13–14 | 48.15% |
| CDM02 vs Hwoarang | 4–20 | 16.67% |
| CDM02 vs Lili | 12–10 | 54.55% |
| CDM02 vs Armor King | 8–14 | 36.36% |
| CDM02 vs King | 13–7 | 65.00% |
| CDM02 vs Paul | 11–8 | 57.89% |
| CDM02 vs Xiaoyu | 7–12 | 36.84% |
| CDM02 vs Yoshimitsu | 10–8 | 55.56% |
| CDM02 vs Devil Jin | 8–10 | 44.44% |
| CDM02 vs Azucena | 8–8 | 50.00% |
| CDM02 vs Feng | 7–8 | 46.67% |
| CDM02 vs Victor | 7–8 | 46.67% |
| CDM02 vs Lidia | 6–9 | 40.00% |
| CDM02 vs Dragunov | 5–9 | 35.71% |
| CDM02 vs Bryan | 5–8 | 38.46% |
| CDM02 vs Asuka | 8–5 | 61.54% |
| CDM02 vs Lee | 5–7 | 41.67% |
| CDM02 vs Jun | 4–8 | 33.33% |
| CDM02 vs Fahkumram | 6–5 | 54.55% |
| CDM02 vs Alisa | 5–5 | 50.00% |
| CDM02 vs Eddy | 5–5 | 50.00% |
| CDM02 vs Lars | 4–3 | 57.14% |
| CDM02 vs Nina | 5–2 | 71.43% |
| CDM02 vs Clive | 4–3 | 57.14% |
| CDM02 vs Jack-8 | 2–4 | 33.33% |
| CDM02 vs Leo | 3–3 | 50.00% |
| CDM02 vs Zafina | 3–3 | 50.00% |
| CDM02 vs Claudio | 0–4 | 0.00% |
| CDM02 vs Shaheen | 2–1 | 66.67% |
| CDM02 vs Anna | 3–0 | 100.00% |
| CDM02 vs Leroy | 2–0 | 100.00% |
| CDM02 vs Raven | 2–0 | 100.00% |
| CDM02 vs Miary Zo | 2–0 | 100.00% |
| CDM02 vs Kuma | 1–0 | 100.00% |
Limitations
This data is often requested to give insight into which characters you have more trouble with than others, but it is not particularly helpful for that. The main issue is that it is heavily skewed by how strong the opponents you play are.
For example, this data suggests my worst matchup is clearly vs Reina, but that's just because most of those games are vs Yagami.
There is a way to account for this being worked on. The central idea is to assign each matchup a rating vs you which adjusts based on the result, much like the regular rating but also based on the rating of each player. With this, it would give a better summary of how well you perform vs each character.
In the meantime, this page is here to present the data as requested.